These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 22475324)

  • 1. Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.
    Walter E; Schmitt T; Dietrich S; Ho A; Witzens-Harig M
    Leuk Lymphoma; 2012 Nov; 53(11):2290-2. PubMed ID: 22475324
    [No Abstract]   [Full Text] [Related]  

  • 2. High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?
    George A; Tam CS; Seymour JF
    Leuk Lymphoma; 2013 Dec; 54(12):2575-6. PubMed ID: 23597141
    [No Abstract]   [Full Text] [Related]  

  • 3. A treatment for activated B-cell-like DLBCL?
    Zinzani PL
    Lancet Oncol; 2014 Aug; 15(9):916-7. PubMed ID: 25042201
    [No Abstract]   [Full Text] [Related]  

  • 4. [Richter syndrome: report of a case].
    Chen DB; Song QJ; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2010 Jul; 39(7):487-8. PubMed ID: 21055184
    [No Abstract]   [Full Text] [Related]  

  • 5. [Primary diffuse large B-cell lymphoma in uterine corpus: report of a case].
    Dong W; Cao L; Wang DS
    Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):270-2. PubMed ID: 21616007
    [No Abstract]   [Full Text] [Related]  

  • 6. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
    Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma.
    Coiffier B; Salles G
    Blood; 2004 Sep; 104(5):1584-5; author reply 1585-6. PubMed ID: 15317734
    [No Abstract]   [Full Text] [Related]  

  • 8. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
    N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete remission of primary cutaneous intravascular large B-cell lymphoma with R-CHOP followed by rituximab monotherapy.
    Pantelaki I; Tigges C; Nußbaum T; Oellig F; Wieland U; Kreuter A
    Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28508527
    [No Abstract]   [Full Text] [Related]  

  • 10. Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy?
    Mondello P; Cuzzocrea S; Pitini V; Aloisi C; Mian M
    Acta Oncol; 2015 Jun; 54(6):953-5. PubMed ID: 25831143
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.
    Koh YW; Hwang HS; Park CS; Yoon DH; Suh C; Huh J
    Leuk Lymphoma; 2015; 56(9):2630-6. PubMed ID: 25573205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study.
    Yamamoto W; Nakamura N; Tomita N; Takeuchi K; Ishii Y; Takahashi H; Watanabe R; Takasaki H; Motomura S; Kobayashi S; Yokose T; Ishigatsubo Y; Sakai R
    Leuk Lymphoma; 2014 Dec; 55(12):2721-7. PubMed ID: 24528218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphism at
    Bashash M; Connors JM; Gascoyne RD; Meissner B; Schuetz JM; Leach S; Slack GW; Berry BR; Hu H; Sehn LH; Brooks-Wilson AR; Spinelli JJ
    Haematologica; 2017 May; 102(5):e199-e202. PubMed ID: 28154089
    [No Abstract]   [Full Text] [Related]  

  • 14. Cirrhosis and intestinal B-cell lymphoma: two entities that are rarely associated with celiac disease.
    Duman AE; Oğütmen Koç D; Korkmaz U; Tohumcu A; Celebi A; Sentürk O; Hülagü S; Erçin C
    Turk J Gastroenterol; 2013; 24(2):192-4. PubMed ID: 23934474
    [No Abstract]   [Full Text] [Related]  

  • 15. Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas.
    Pfreundschuh M
    J Clin Oncol; 2012 Oct; 30(28):3433-5. PubMed ID: 22949148
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.
    Arakaki H; Nakazato T; Osada Y; Ito C; Aisa Y; Mori T
    Ann Hematol; 2017 Jul; 96(7):1225-1226. PubMed ID: 28508175
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma.
    Dakhil S; Hermann R; Schreeder MT; Gregory SA; Monte M; Windsor KS; Hurst D; Chai A; Brewster M; Richards P
    Leuk Lymphoma; 2014 Oct; 55(10):2335-40. PubMed ID: 24471908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD30, another useful predictor of survival in DLBCL?
    Chan WC
    Blood; 2013 Apr; 121(14):2582-3. PubMed ID: 23557969
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP.
    Ribera JM; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M; Navarro JT; Feliu E
    Br J Haematol; 2012 Jun; 157(5):637-9. PubMed ID: 22313456
    [No Abstract]   [Full Text] [Related]  

  • 20. TP53 mutations and rituximab-CHOP.
    Gisselbrecht C
    Blood; 2012 Nov; 120(19):3867-9. PubMed ID: 23144158
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.